title: Systematic review and economic evaluation of Helicobacter pylori eradication treatment for non-ulcer dyspepsia. Dyspepsia Review Group.
abstract: OBJECTIVE
  To evaluate efficacy and cost effectiveness of Helicobacter pylori eradication treatment in patients with non-ulcer dyspepsia infected with H pylori.
  
  
  METHODS
  Systematic review of randomised controlled trials comparing H pylori eradication with placebo or another drug treatment. Results were incorporated into a Markov model comparing health service costs and benefits of H pylori eradication with antacid treatment over one year.
  
  
  METHODS
  Six electronic databases were searched for randomised controlled trials from January 1966 to May 2000. Experts in the field, pharmaceutical companies, and journals were contacted for information on any unpublished trials. Trial reports were reviewed according to predefined eligibility and quality criteria.
  
  
  METHODS
  Relative risk reduction for remaining dyspeptic symptoms (the same or worse) at 3-12 months. Cost per dyspepsia-free month estimated from Markov model based on estimated relative risk reduction.
  
  
  RESULTS
  Twelve trials were included in the systematic review, nine of which evaluated dyspepsia at 3-12 months in 2541 patients. H pylori eradication treatment was significantly superior to placebo in treating non-ulcer dyspepsia (relative risk reduction 9% (95% confidence interval 4% to 14%)), one case of dyspepsia being cured for every 15 people treated. H pylori eradication cost pound56 per dyspepsia-free month during first year after treatment.
  
  
  CONCLUSIONS
  H pylori eradication may be cost effective treatment for non-ulcer dyspepsia in infected patients but further evidence is needed on decision makers' willingness to pay for relief of dyspepsia.
authors.affiliation: Gastroenterology Unit, Centre for Digestive Diseases, General Infirmary at Leeds, Leeds LS1 3EX.
authors.forename: P
authors.initials: P
authors.lastname: Moayyedi
authors.forename: S
authors.initials: S
authors.lastname: Soo
authors.forename: J
authors.initials: J
authors.lastname: Deeks
authors.forename: D
authors.initials: D
authors.lastname: Forman
authors.forename: J
authors.initials: J
authors.lastname: Mason
authors.forename: M
authors.initials: M
authors.lastname: Innes
authors.forename: B
authors.initials: B
authors.lastname: Delaney
mesh_terms: D000863:Antacids / Q000191:economics / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000191:economics / Q000627:therapeutic use*; D003362:Cost-Benefit Analysis; D016527:Drug Costs; D004415:Dyspepsia / Q000188:drug therapy* / Q000382:microbiology; D016481:Helicobacter Infections / Q000188:drug therapy*; D016480:Helicobacter pylori; D006801:Humans; D016247:Information Storage and Retrieval; D008390:Markov Chains; D016032:Randomized Controlled Trials as Topic; D012306:Risk
chemical_list: D000863:Antacids; D000900:Anti-Bacterial Agents